Histotripsy Ablation of Spontaneously Occurring Canine Bone Tumors

• Published in: IEEE transactions on biomedical engineering Vol. 70; no. 1; pp. 331 - 342
• Main Authors: Ruger, Lauren N., Hay, Alayna N., Gannon, Jessica M., Sheppard, Hannah O., Coutermarsh-Ott, Sheryl L., Daniel, Gregory B., Kierski, Katharine R., Ciepluch, Brittany J., Vlaisavljevich, Eli, Tuohy, Joanne L.
• Format: Journal Article
• Language: English
• Published: New York IEEE 01-01-2023; The Institute of Electrical and Electronics Engineers, Inc. (IEEE)
• Subjects: Ablation; Amputation; Bone cancer; Bone tumors; Bones; canine; Computed tomography; Dogs; focused ultrasound; histotripsy; Osteosarcoma; Patients; Pulse repetition frequency; Surgery; Transducers; Tumors; Ultrasonic imaging
• DOI: 10.1109/TBME.2022.3191069
• EISSN: 1558-2531
• ISSN: 0018-9294

Objective: Osteosarcoma (OS) is a devastating primary bone tumor in dogs and humans with limited non-surgical treatment options. As the first completely non-invasive and non-thermal ablation technique, histotripsy has the potential to significantly improve the standard of care for patients with primary bone tumors. Introduction: Standard of care treatment for primary appendicular OS involves surgical resection via either limb amputation or limb-salvage surgery for suitable candidates. Biological similarities between canine and human OS make the dog an informative comparative oncology research model to advance treatment options for primary OS. Evaluating histotripsy for ablating spontaneous canine primary OS will build a foundation upon which histotripsy can be translated clinically into a standard of care therapy for canine and human OS. Methods: Five dogs with suspected spontaneous OS were treated with a 500 kHz histotripsy system guided by real-time ultrasound image guidance. Spherical ablation volumes within each tumor (1.25-3 cm in diameter) were treated with single cycle histotripsy pulses applied at a pulse repetition frequency of 500 Hz and a dose of 500 pulses/point. Results: Tumor ablation was successfully identified grossly and histologically within the targeted treatment regions of all subjects. Histotripsy treatments were well-tolerated amongst all patients with no significant clinical adverse effects. Conclusion & Significance: Histotripsy safely and effectively ablated the targeted treatment volumes in all subjects, demonstrating its potential to serve as a non-invasive treatment modality for primary bone tumors.